Rocket Pharmaceuticals (RCKT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$369.6 million.
- Rocket Pharmaceuticals' Enterprise Value rose 890.99% to -$369.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$369.6 million, marking a year-over-year increase of 890.99%. This contributed to the annual value of -$372.3 million for FY2024, which is 22.48% up from last year.
- Latest data reveals that Rocket Pharmaceuticals reported Enterprise Value of -$369.6 million as of Q3 2025, which was up 890.99% from -$510.2 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Enterprise Value ranged from a high of -$356.4 million in Q4 2022 and a low of -$680.2 million during Q1 2021
- Moreover, its 5-year median value for Enterprise Value was -$519.0 million (2024), whereas its average is -$508.0 million.
- As far as peak fluctuations go, Rocket Pharmaceuticals' Enterprise Value plummeted by 8828.12% in 2021, and later surged by 3745.12% in 2024.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Enterprise Value stood at -$388.7 million in 2021, then grew by 8.32% to -$356.4 million in 2022, then dropped by 4.71% to -$373.2 million in 2023, then rose by 0.22% to -$372.3 million in 2024, then increased by 0.73% to -$369.6 million in 2025.
- Its Enterprise Value was -$369.6 million in Q3 2025, compared to -$510.2 million in Q2 2025 and -$586.6 million in Q1 2025.